(2S,4R)-tert-butyl 2-ethynyl-4-hydroxypyrrolidine-1-carboxylate | 275387-87-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (2S,4R)-tert-butyl 2-ethynyl-4-hydroxypyrrolidine-1-carboxylate
• 英文别名: (3S,5S)-N-Boc-5-ethynyl-3-hydroxy-pyrrolidine；tert-butyl (2S,4S)-2-ethynyl-4-hydroxypyrrolidine-1-carboxylate
• CAS: 275387-87-6
• 化学式: C₁₁H₁₇NO₃
• 分子量: 211.261
• InChiKey: PEEDRTKUXJHIQB-BDAKNGLRSA-N

物化性质

• 沸点：
  297.2±40.0 °C(Predicted)
• 密度：
  1.13±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (2S,4R)-tert-butyl 2-ethynyl-4-hydroxypyrrolidine-1-carboxylate 在 copper(l) iodide 、 dichlorobis(triphenylphosphine)palladium[II] 、 sodium hydride 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 22.0h， 生成 3-ethyl-4-(7-fluoro-3-(4-(((2S,4S)-4-methoxypyrrolidin-2-yl)ethynyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)phenol
  参考文献：
  名称：

  [EN] BICYCLIC INHIBITORS OF JAK AND METHODS OF USE
  [FR] INHIBITEURS BICYCLIQUES DE JAK ET PROCÉDÉS D'UTILISATION

  摘要：

  The present disclosure provides inhibitors of the Janus family of tyrosine kinases (JAK). Also disclosed are methods to modulate the activity of JAK and methods of treatment of disorders mediated by JAK.

  公开号：

  WO2023091707A1
• 作为产物：
  描述：

  tert-butyl (2S,4S)-4-((tert-butyldiphenylsilyl)oxy)-2-ethynylpyrrolidine-1-carboxylate 在 四丁基氟化铵 作用下， 以 四氢呋喃 为溶剂， 以90%的产率得到(2S,4R)-tert-butyl 2-ethynyl-4-hydroxypyrrolidine-1-carboxylate
  参考文献：
  名称：

  Synthesis and stereochemical effects of pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines as EGFR and ErbB-2 inhibitors

  摘要：

  A novel class of pyrrolidinyl-acetyleneic thieno[3,2-d]pyrimidines has been identified which potently inhibit the EGFR and ErbB-2 receptor tyrosine kinases. Synthetic modifications of the pyrrolidine carbamate moiety result in a range of effects on enzyme and cellular potency. In addition, the impact of the absolute stereochemical configuration on cellular potency and oral mouse pharmacokinetics is described. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.11.023

文献信息

• ANTITUMOR DRUG FOR INTERMITTENT ADMINISTRATION OF FGFR INHIBITOR
  申请人：TAIHO PHARMACEUTICAL CO., LTD.

  公开号：US20160193210A1

  公开（公告）日：2016-07-07

  The problem to be solved by the present invention is to provide a potent and highly selective novel FGFR inhibitor, and an antitumor agent having reduced side effects, such as increased blood phosphorus levels, while maintaining the antitumor effect of the FGFR inhibitor. The present invention provides an antitumor agent comprising a 3,5-disubstituted benzene alkynyl compound represented by Formula (I) or a salt thereof that is used so that the 3,5-disubstituted benzene alkynyl compound or a salt thereof is administered on an administration schedule of at least twice a week and a dosing interval of at least one day.

  本发明要解决的问题是提供一种有效且高选择性的新型FGFR抑制剂，以及具有减少副作用（如增加血磷水平）的抗肿瘤药剂，同时保持FGFR抑制剂的抗肿瘤效果。本发明提供了一种抗肿瘤药剂，包括由式（I）表示的3,5-二取代苯基炔基化合物或其盐，该药剂用于按照至少每周两次和至少间隔一天的给药计划给予3,5-二取代苯基炔基化合物或其盐。
• [EN] 4-ALKENYL (AND ALKYNYL) OXINDOLES AS INHIBITORS OF CYCLIN-DEPENDENT KINASES, IN PARTICULAR CDK2<br/>[FR] 4-ALCENYL (ET ALCYNYL) OXINDOLES UTILISES COMME INHIBITEURS DE KINASES DEPENDANTES DES CYCLINES, EN PARTICULIER LA CDK2
  申请人：HOFFMANN LA ROCHE

  公开号：WO2000035908A1

  公开（公告）日：2000-06-22

  Novel 4-alkenyl- and 4-alkynyl oxindoles having formulas (I) and (II) and the pharmaceutically acceptable salts thereof, wherein R?1, R2, R3¿, a, b, and X are as defined herein inhibit cyclin-dependent kinases (CDKs), in particular CDK2 and are useful as anti-proliferative agents in the treatment or control of cell proliferative disorders, in particular breast and colon tumors.

  具有以下化学式（I）和（II）以及其药学上可接受的盐的新型4-烯基和4-炔基氧吲哚，其中R?1，R2，R3¿，a，b和X如此定义，抑制细胞周期依赖性激酶（CDKs），特别是CDK2，并且在治疗或控制细胞增殖性疾病，特别是乳腺和结肠肿瘤中作为抗增殖剂是有用的。
• 4-alkenyl-and 4-alkynyloxindoles
  申请人：Hoffmann-La Roche Inc.

  公开号：US06252086B1

  公开（公告）日：2001-06-26

  Disclosed are novel 4-alkenyl- and 4-alkynyl oxindoles having the formula and the pharmaceutically acceptable salts thereof. These compounds inhibit cyclin-dependent kinases (CDKs), in particular CDK2. These compounds and their pharmaceutically acceptable salts, and prodrugs of said compounds, are anti-proliferative agents useful in the treatment or control of cell proliferative disorders, in particular cancer, more particularly, the treatment or control of breast and colon tumors. Also disclosed are pharmaceutical compositions containing the compounds of formula I and II as well as intermediates useful in the preparation of the compounds of formula I and II.

  本发明涉及具有以下公式和其药学上可接受的盐的新型4-烯基和4-炔基氧吲哚。这些化合物抑制细胞周期蛋白依赖性激酶（CDKs），特别是CDK2。这些化合物及其药学上可接受的盐和前药是抗增殖剂，可用于治疗或控制细胞增殖性疾病，特别是癌症，更特别是乳腺和结肠肿瘤的治疗或控制。本发明还涉及包含公式I和II的化合物的制药组合物，以及制备公式I和II的化合物的中间体。
• 4-Alkenyl- and 4-alkynyloxindoles
  申请人：Hoffmann-La Roche Inc.

  公开号：US06130239A1

  公开（公告）日：2000-10-10

  Disclosed are novel 4-alkenyl- and 4-alkynyl oxindoles having the formula ##STR1## and the pharmaceutically acceptable salts thereof, wherein R.sup.1, R.sup.2, R.sup.3, a, b, and X are as defined herein. These compounds inhibit cyclin-dependent kinases (CDKs), in particular CDK2. These compounds and their pharmaceutically acceptable salts, and prodrugs of said compounds, are anti-proliferative agents useful in the treatment or control of cell proliferative disorders, in particular cancer, more particularly, the treatment or control of breast and colon tumors. Also disclosed are pharmaceutical compositions containing the compounds of formula I and II as well as intermediates useful in the preparation of the compounds of formula I and II.

  本发明涉及一种新型的4-烯基和4-炔基吲哚，其化学式为##STR1##以及其药学上可接受的盐，其中R.sup.1，R.sup.2，R.sup.3，a，b和X的定义如本文所述。这些化合物抑制细胞周期依赖性激酶（CDKs），特别是CDK2。这些化合物及其药学上可接受的盐和前药是抗增殖剂，用于治疗或控制细胞增殖性疾病，特别是癌症，更特别是用于治疗或控制乳腺和结肠肿瘤。本发明还涉及包含化合物I和II的制药组合物，以及用于制备化合物I和II的中间体。
• Dual EGFR/ErbB-2 inhibitors from novel pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines
  作者：Robert D. Hubbard、Scott H. Dickerson、Holly K. Emerson、Robert J. Griffin、Michael J. Reno、Keith R. Hornberger、David W. Rusnak、Edgar R. Wood、David E. Uehling、Alex G. Waterson

  DOI：10.1016/j.bmcl.2008.09.090

  日期：2008.11

  A novel class of substituted pyrrolidinyl-acetylenic thieno[3,2-d] pyrimidines has been identified that are potent and selective inhibitors of both EGFR/ErbB-2 receptor tyrosine kinases. The inhibitors are found to display a range of enzyme and cellular potency and also to display a varying level of covalent modi. cation of the kinase targets. Selected molecules, including compound 15h, were found to be potent in enzymatic and cellular assays while also demonstrating exposure in the mouse from an oral dose. (C) 2008 Elsevier Ltd. All rights reserved.